Natco moves to oppose Gilead hepatitis C drug patent in India: source

India's Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's breakthrough hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said. Natco has filed a so-called "pre-grant opposition" with India's Controller General of Patents, Designs & Trademarks, said the source, who declined to be named because the information was not public yet. India's patent laws allow a third party to dispute the validity of a pending patent application.



via Health News Headlines - Yahoo News http://ift.tt/1n7DDTA